Unleashing the Power of Tregs

Multiple Treg therapeutic modalities addressing neurodegenerative, autoimmune, and metabolic diseases

We are a clinical-stage company focused on developing our multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.

Strong proof of concept data in Amyotrophic Lateral Sclerosis (ALS) and Alzheimer’s

Treg Enhancing Biologics:

Treg Enhancing
Biologics:
Allogeneic Treg
Derived Exosomes:
Autologous Treg
Cell Therapy:

Video

News

Keep up-to-date with the latest news about Coya Therapeutics.

The gross proceeds to the Company from the private placement were $26.5 million and net proceeds are expected to be approximately $24.1 million. The Company...

Coya Therapeutics to Present Data on Immune System and Regulatory T Cell (Treg) Contributions in Frontotemporal Dementia (FTD) Patients at AD/PD 2024 Conference

Feb 29, 2024

Dr. Fred Grossman, Coya’s Chief Medical Officer, stated: “As will be demonstrated in this data, FTD is characterized by pronounced inflammation from compromised Treg cells...

Coya Therapeutics to Present Novel Biomarker Survival Data in Large Cohort of ALS (Amyotrophic Lateral Sclerosis) Patients at Society of Neuroimmune Pharmacology Conference

Feb 22, 2024

Just over two months ago we announced our partnership with Dr. Reddy’s Laboratories for COYA 302 in Amyotrophic Lateral Sclerosis (ALS), our lead product candidate...

Coya Therapeutics Issues Letter to Stockholders Highlighting Expansion of COYA 302 into Alzheimer’s Disease and Coya’s Pathway to a “Pipeline in a Product”

Feb 21, 2024

Just over two months ago we announced our partnership with Dr. Reddy’s Laboratories for COYA 302 in Amyotrophic Lateral Sclerosis (ALS), our lead product candidate...

Coya Therapeutics Licenses Intellectual Property Rights for Use of Next Generation Immune Modulatory Biologics in Combination with COYA 301 to Enhance Regulatory T Cells (Tregs) in Inflammatory Diseases

Feb 13, 2024
HOUSTON--(BUSINESS WIRE)-- Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic programs intended to enhance regulatory T cell...

Coya Therapeutics Announces Closing of $26.5 Million Private Placement

Jan. 29, 2024
The gross proceeds to the Company from the private placement were $26.5 million and net proceeds are expected to be approximately $24.1 million. The Company...

Coya Therapeutics to Participate in Upcoming Chardan Biotech Leadership Call Series

Jan. 18, 2024

Chardan’s Leadership Call Series features management teams from leading disruptive biotechnology companies discussing their business and key industry trends in a fireside chat-style format. This...